Background: Results of previous clinical trials evaluating the effect of magnesium supplementation on
inflammatory markers are controversial.
Objective: A systematic review and meta-analysis of randomized controlled trials (RCTs) were performed to
evaluating the effect of oral magnesium supplementation on plasma C-reactive protein (CRP) concentrations.
Method: PubMed-Medline, SCOPUS, Web of Science and Google Scholar databases were searched (from inception
to August 09, 2016) to identify RCTs, evaluating the effect of magnesium on CRP levels. A random-effects
model and a generic inverse variance method were used to compensate for the heterogeneity of studies. Publication
bias, sensitivity analysis, and meta-regression assessments were conducted using standard methods.
Results: Overall, the impact of magnesium supplementation on plasma concentrations of CRP was assessed in 11
studies. Magnesium treatment was not found to significantly affect plasma concentrations of CRP (WMD: -0.11
mg/L, 95% CI: -0.75, 0.52, p=0.727). When the analysis was stratified to compare subgroups of studies in populations
with baseline plasma CRP values of ≤ 3 and > 3 mg/L, a significant reduction of CRP values was observed
in the latter subgroup (WMD: -1.12 mg/L, 95% CI: -2.05, -0.18, p=0.019) but not in the former group (WMD:
0.61 mg/L, 95% CI: -0.10, 1.32, p=0.090). The difference between subgroups was statistically significant
Conclusion: Results of the present meta-analysis indicated that magnesium supplementation reduces CRP levels
among individuals with inflammation (CRP levels > 3 mg/dL). This finding suggests that magnesium supplements
may have a beneficial role as an adjuvant for the management of low-grade chronic systemic inflammation.